Lianhuan Pharmaceutical wins China approval for bilastine API

November 20, 2026  Source: drugdu 37

"/
On November 19, Lianhuan Pharmaceutical announced that China’s National Medical Products Administration had approved its marketing application for bilastine API. Bilastine is a long-acting, nonsedating antihistamine that selectively antagonizes peripheral H1 receptors. It has no affinity for muscarinic receptors and low affinity for other receptors.

Source: http://finance.eastmoney.com/a/202611193935255859.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.